Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Urinary Bladder Neoplasms 1Solid Tumours 1Pancreatic Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Dermatofibrosarcoma 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × brigimadlin × Clear all
NCT05376800 2025-08-24

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Boehringer Ingelheim

Phase 1 Completed
24 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡